(VIANEWS) – Shares of BERGENBIO (Oslo Børs Benchmark Index_GI: BGBIO.OL) dropped by a staggering 11.14% to kr0.34 at 11:22 EST on Monday, after two consecutive sessions in a row of gains. Oslo Børs Benchmark Index_GI is jumping 0.55% to kr1,233.00, after two successive sessions in a row of gains. This seems, up to now, a somewhat bullish trend trading session today.
About BERGENBIO
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
Earnings Per Share
As for profitability, BERGENBIO has a trailing twelve months EPS of kr-3.74.
Volatility
BERGENBIO’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.80%, a negative 4.15%, and a positive 8.17%.
BERGENBIO’s highest amplitude of average volatility was 13.27% (last week), 21.94% (last month), and 8.17% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BERGENBIO’s stock is considered to be oversold (<=20).
Volume
Today’s last reported volume for BERGENBIO is 3331880 which is 100.33% above its average volume of 1663150.
More news about BERGENBIO (BGBIO.OL).
